Silence Therapeutics (SLN) Operating Expenses (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Operating Expenses data on file, last reported at $16.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 13245.45% year-over-year to $16.1 million; the trailing twelve-month figure through Mar 2026 stood at $42.8 million (down 15.95% YoY), and the FY2025 full-year result was $28.5 million, up 250.95% from the prior year.
• Operating Expenses improved to $16.1 million in Q1 2026, from $4.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.7 million in Q4 2024 to a low of -$3.9 million in Q2 2024.
• A 3-year average of $10.0 million and a median of $4.3 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses tumbled 90.51% in 2025 and soared 13245.45% in 2026, its largest moves.
• Tracing SLN's Operating Expenses over 3 years: stood at $45.7 million in 2024, then plunged by 90.51% to $4.3 million in 2025, then surged by 272.42% to $16.1 million in 2026.
• Business Quant data shows SLN's Operating Expenses at $16.1 million in Q1 2026, $4.3 million in Q4 2025, and $18.9 million in Q3 2025.